BTOG 2019 | The potential of targeted and immune therapies in SCLC
Small cell lung cancer (SCLC) has a poor prognosis, often diagnosed at an advanced stage and with limited treatment options. Here, Martin Reck, MD, PhD, of Hospital Grosshansdorf, Grosshansdorf, Germany, considers the potential of targeted and immune therapies for SCLC. Prof. Reck highlights relatively recent data showing a benefit with atezolizumab and chemotherapy, although the increment of improvement produced is debated. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.
Get great new content delivered to your inboxSign up